

TENNESSEE GENERAL ASSEMBLY
FISCAL REVIEW COMMITTEE



FISCAL NOTE

SB 2240 - HB 2335

February 16, 2022

SUMMARY OF BILL: Requires the Department of Mental Health and Substance Abuse Services (DMHSAS) to study the effects that current rules regarding the prescribing of buprenorphine products have in nonresidential office-based opiate treatment facilities, nonresidential substitution-based treatment centers for opiate addiction, pharmacies, and hospitals for calendar years 2019-2021. Requires that DMHSAS reports its findings and recommendations to the Senate Health and Welfare Committee and the House Health Committee no later than February 1, 2023.

FISCAL IMPACT:

NOT SIGNIFICANT

Assumption:

- Based on information provided by DMHSAS, the study can be completed using existing resources and personnel, without a significant increase in state expenditures.

CERTIFICATION:

The information contained herein is true and correct to the best of my knowledge.

A handwritten signature in black ink that reads "Krista Lee Carsner".

Krista Lee Carsner, Executive Director

/cd

SB 2240 - HB 2335